chronic
myeloid
leukemia
cml
myeloprolif
disord
character
presenc
philadelphia
chromosom
abnorm
clone
hematopoiet
cell
imatinib
mesyl
imatinib
first
approv
tyrosin
kinas
inhibitor
tki
frontlin
treatment
philadelphia
chromosomeposit
ph
cml
commonli
report
side
effect
clinic
use
tki
includ
lung
injuri
repair
loss
stem
cell
epitheli
surfac
drugassoci
cell
injuri
howev
advers
reaction
depend
individu
suscept
imatinib
gener
toler
well
patient
although
use
high
dose
caus
grade
nonhematolog
toxic
sever
pulmonari
advers
event
earli
chronic
phase
cml
imatinibinduc
interstiti
lung
diseas
ild
rare
occurr
unclear
clinic
featur
report
rare
case
involv
man
cml
develop
acut
irrevers
interstiti
pneumon
month
treatment
imatinib
chines
man
present
ningbo
first
hospit
ningbo
china
chief
complaint
chronic
fatigu
white
blood
cell
wbc
count
neutrophil
basophil
granulocyt
hemoglobin
platelet
level
gl
respect
spleen
could
palpat
cm
costal
margin
ultrasound
confirm
splenomegali
bone
marrow
punctur
show
granulocyt
hyperplasia
myeloblast
promyelocyt
respect
patient
diagnos
chronic
phase
cml
philadelphia
chromosom
posit
daili
treatment
mg
oral
imatinib
initi
toler
well
patient
exhibit
complet
hematolog
respons
major
molecular
respons
bcrabl
found
revers
transcript
polymeras
chain
reaction
rtpcr
month
treatment
druginduc
advers
effect
minim
imatinib
treatment
continu
anoth
month
timelin
intervent
outcom
shown
figur
month
imatinib
treatment
patient
present
depart
pneumolog
ningbo
hospit
cough
fever
find
physic
examin
unremark
patient
oxygen
satur
chest
comput
tomographi
ct
show
dens
cordshap
gridshap
fiber
distribut
along
surround
bronchi
lung
particularli
upper
lobe
involv
find
typic
interstiti
pneumonia
fig
lung
function
test
demonstr
sever
impair
diffus
diffus
capac
lung
carbon
monoxid
dlco
mmolminkpa
predict
forc
expiratori
volum
forc
vital
capac
l
predict
l
predict
respect
creactiv
protein
level
normal
mgl
patient
diagnos
pneumonia
treat
piperacillintazobactam
time
repeat
examin
acidfast
bacilli
sputum
provid
neg
result
moreov
result
test
ebv
viru
antibodi
cytomegaloviru
cmv
antibodi
mycoplasma
pneumonia
antibodi
immunoglobulin
ig
rubella
antibodi
toxoplasma
igm
antibodi
herp
simplex
viru
hsv
igm
antibodi
serum
ige
serum
igg
rheumat
neg
howev
littl
improv
week
treatment
suspect
imatinibinduc
ild
discontinu
imatinib
treatment
prednison
mgkgday
initi
dose
taper
mgkgday
week
later
patient
experienc
relief
cough
fever
although
chest
ct
show
littl
improv
fig
howev
lung
function
test
show
evid
improv
dlco
mmolmin
kpa
predict
l
predict
forc
vital
capac
l
predict
prednison
treatment
continu
month
follow
rtpcr
show
bcrabl
level
although
imatinib
result
ild
also
proven
benefici
patient
therefor
month
later
patient
insist
resum
imatinib
treatment
continu
take
prednison
mgkg
mg
howev
show
intoler
imatinib
within
week
resum
drug
exhibit
aggrav
dyspnea
cough
discontinu
imatinib
increas
prednison
dosag
mgkgday
clinic
symptom
disappear
soon
nilotinib
administ
altern
drug
week
later
prednison
dose
gradual
taper
follow
drug
discontinu
time
write
report
month
imatinib
withdrawn
patient
toler
nilotinib
well
consider
amelior
clinic
symptom
lung
function
test
show
dlco
mmolminkpa
predict
l
predict
forc
vital
capac
l
predict
howev
pulmonari
ct
perform
month
imatinib
withdraw
show
irrevers
pulmonari
interstiti
fibrosi
without
progress
fig
ild
lung
disord
caus
sever
substanc
radiotherapi
diseas
progress
diseas
prove
fatal
earli
recognit
essenti
case
report
possibl
pathogenes
tuberculosi
cmv
infect
ebv
infect
pneumonia
infect
rubella
toxoplasmosi
hsv
rule
prednison
treatment
initi
test
rheumat
also
show
neg
result
peripher
eosinophil
account
wbc
find
exclud
immun
allerg
mechan
imatinib
first
clinic
use
tki
treatment
cml
although
mechan
caus
lung
injuri
ild
remain
unclear
one
japanes
studi
includ
patient
ild
treat
imatinib
vari
ct
find
document
howev
diffus
alveolar
damag
observ
among
patient
receiv
prednison
receiv
high
dose
five
receiv
moder
dose
remain
three
patient
untreat
treat
patient
exhibit
improv
recov
five
patient
show
improv
imatinibinduc
ild
like
develop
previou
damag
lung
lung
histori
tuberculosi
mechan
lung
injuri
possibl
relat
inhibit
plateletderiv
growth
factor
receptor
imatinib
patient
histori
smoke
lung
diseas
tumor
rheumat
diseas
exclud
laboratori
test
reintroduct
imatinib
caus
diseas
relaps
consist
find
previou
studi
contrast
anoth
case
report
document
success
rechalleng
imatinib
patient
imatinibinduc
pneumon
patient
show
obviou
improv
imag
find
prednison
treatment
moreov
show
poor
toler
imatinib
reintroduc
treatment
regimen
nevertheless
clinic
symptom
disappear
lung
function
improv
allow
resum
daili
activ
work
interest
find
present
case
recoveri
lung
function
despit
lack
improv
imag
find
followup
period
almost
year
phenomenon
gener
observ
patient
sever
acut
respiratori
syndrom
imag
find
improv
despit
clinic
improv
condit
precis
reason
find
patient
remain
unclear
predict
whether
ct
find
improv
time
hope
get
clariti
continu
monitor
patient
nilotinib
analog
imatinib
block
bcrabl
kinas
higher
intens
nilotinib
approv
use
patient
cml
show
imatinib
resist
intoler
previou
studi
show
lung
abnorm
caus
imatinib
could
revers
approxim
month
switch
nilotinib
treatment
imatinib
intoler
may
occasion
occur
dose
increas
nilotinib
play
import
role
subsequ
treatment
case
howev
remain
unclear
whether
patient
toler
initi
dose
imatinib
recov
lung
damag
present
case
patient
toler
imatinib
rechalleng
eventu
switch
nilotinib
follow
lung
function
improv
improv
fibrosi
irrevers
lung
fibrosi
could
caus
imatinib
rechalleng
although
confirm
previou
report
document
irrevers
architectur
distort
patient
use
imatinib
year
thu
sever
imatinibinduc
lung
damag
seem
timedepend
particularli
doseindepend
patient
howev
exact
treatment
durat
caus
irrevers
damag
remain
unclear
accord
experi
report
durat
probabl
month
conclus
report
rare
case
imatinibinduc
sever
irrevers
ild
patient
cml
show
complet
recoveri
despit
imatinib
discontinu
prednison
treatment
possibl
reason
longterm
use
imatinib
month
find
case
suggest
clinician
consid
possibl
sever
irrevers
ild
care
monitor
patient
receiv
imatinib
treatment
data
curat
jingfeng
huang
fangfang
jin
jiaohai
pan
guifang
ouyang
formal
analysi
jiaohai
pan
fund
acquisit
ping
zhang
investig
guifang
ouyang
project
administr
guifang
ouyang
write
origin
draft
ping
zhang
jingfeng
huang
write
review
edit
ping
zhang
guifang
ouyang
ping
zhang
ping
zhang
orcid
